LAVA Therapeutics (NASDAQ:LVTX) Stock Price Down 2.3%

LAVA Therapeutics (NASDAQ:LVTX) shares fell 2.3% on Friday . The stock traded as low as $2.96 and last traded at $3.03. 47,453 shares were traded during trading, a decline of 96% from the average session volume of 1,352,372 shares. The stock had previously closed at $3.10.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a research note on Thursday, March 21st.

LAVA Therapeutics Stock Performance

The company has a current ratio of 6.62, a quick ratio of 6.62 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average price of $2.90 and a 200-day moving average price of $2.03.

LAVA Therapeutics (NASDAQ:LVTX) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of $0.16 by ($0.40). LAVA Therapeutics had a negative net margin of 620.09% and a negative return on equity of 68.54%. The business had revenue of $0.35 million for the quarter, compared to the consensus estimate of $25.00 million. As a group, equities analysts forecast that LAVA Therapeutics will post -1.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in LAVA Therapeutics stock. Pathway Financial Advisors LLC acquired a new stake in shares of LAVA Therapeutics (NASDAQ:LVTX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,000 shares of the company’s stock, valued at approximately $47,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.